Note: This version of FlowJo is compatible with FlowJo Enterprise v2.0 or the newly released FlowJo Enterprise 2.1. Improved interactions with BD® Research Cloud: Save and load options throughout the software now include the BD ® Research Cloud as an option.Native Cluster Explorer: Display line charts, bar charts, heat maps, and dimensionality reduction plots of clustered data in FlowJo without the use of a plugin.Clone gates: Gates with the same name can now be linked together as ‘clones’ so that their position is synchronized.Auto-Quad gates: Automatically create quads and rectangle gates based on range gates, bi-sector gates or the data itself.Spectral similarity scores: Calculate the cosine index for acquired data to evaluate reagent choices made in panel design based on data from your specific instrument and experimental conditions.MEM – Marker Enrichment Modeling (MEM): Re-name clusters automatically and quantitatively based on their marker expression with a human- and machine-readable label.Autofluorescence extraction in traditional (gate-based) compensation: Use an unstained cell data file and true zero as the background value to model autofluorescence for extraction.Embed: Forward propagate clustering or dimensionality reduction results to new files with the same parameters.This can only be achieved in collaboration with other stakeholders, and will require more of a systems thinking approach.The study was commissioned by the UK’s Foreign, Commonwealth & Development Office (FCDO, formerly DFID) to inform policy and investment decisions in this field for the UK government and other major government donors and philanthropies including The Wellcome Trust and The Bill & Melinda Gates Foundation. Learning from the pandemic, governments investing in PDPs now have an opportunity to shift from a “market-correcting role” to rethink how public value is imagined, practiced and evaluated to achieve public purpose. Since their inception, the ten PDPs assessed in the study have collectively brought 85 new products to market, including 3 vaccines, 27 therapeutics, 50 diagnostics or health technologies, and 5 vector control tools. All key assumptions that were the basis of the PDP model when it was established 20 years ago – market failure for poverty related diseases, a portfolio approach to product R&D, capacity building in LMICs, cost-effectiveness, and access towards health impact – are still highly relevant today. The findings confirmed that the PDP experiment has been one of the most successful in accelerating the development of products and technologies for poverty related and neglected diseases. PDPs work as virtual orchestras by acting as R&D systems facilitators, aggregating funding and technical expertise from public, private, academic and philanthropic sectors to develop vaccines, drugs and other technologies for diseases of poverty. Research looks at a range of innovative non-profit multi-stakeholder organizations in global health, called product development partnerships (PDPs). This study shows that an alternative R&D model to a purely private sector approach is feasible and has been transformational for global health. When markets and systems fail, all sectors – governments, industry and the civic sector – need to collaborate in new ways for the common good.
0 Comments
Leave a Reply. |